Rarecells

📍 Paris, France👥 29 employees💰 Last funded Dec 2021
Biotechnology Research🌐 rarecells.com
Website LinkedIn
Rarecells develops and commercializes the ISET technology to isolate Circulating Cancer Cells for early cancer diagnosis and medical research. Rarecells® Diagnostics was created in 2010 by Patrizia Paterlini Brechot, Professor of Cell Biology and Oncology, in order to make the scientific and technological advances developed by her team available to research teams and patients. Rarecells® Diagnostics’ core product is the patented ISET® (Isolation by SizE of Tumor cells) Technology. Rarecells® Diagnostics has the exclusive license of patents belonging to the French Public Institutions University Paris Descartes, Assistance Publique Hôpitaux de Paris and INSERM protecting the Rarecells® Device and its consumables, as well as the analyses performed on cells isolated using the Rarecells® System. Rarecells® Diagnostics is a science-driven company. We are scientists working for scientists and patients. We care about bringing benefits to the patients.The team delivers customer satisfaction by manufacturing high quality products and providing high-level scientific assistance. Rarecells® and ISET® are registered trademarks of Rarecells SAS.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
2
Frequently asked questions
Who invested in Rarecells?
Rarecells has 2 investors on record on gritt.io.
When did Rarecells last raise funding?
The most recent investment in Rarecells recorded on gritt.io was in December 2021.
What industry is Rarecells in?
Rarecells operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Rarecells based?
Rarecells is headquartered in Paris, France.